Insight Capital Research & Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Insight Capital Research & Management’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	$248K	Buy	+2,870	New	+$230K	0.14%	96

Other funds holding XBI

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

AssetMark Inc Concord, California $58.2B AUM 22.78% 1-Year Est. Return

Insight Capital Research & Management's XBI Position: Q3 2017 in Review

Insight Capital Research & Management opened a new position in State Street SPDR S&P Biotech ETF (XBI) in Q3 2017: 2,870 shares worth $248K. The stake represents 0.14% of the portfolio and ranks #96 among its holdings.

349 funds tracked by Wall St. Rank hold XBI as of Q3 2017.

Insight Capital Research & Management held 2,870 shares of State Street SPDR S&P Biotech ETF worth $248K as of Q3 2017.
State Street SPDR S&P Biotech ETF was a new Insight Capital Research & Management position in Q3 2017.
State Street SPDR S&P Biotech ETF made up 0.14% of Insight Capital Research & Management's portfolio in Q3 2017, its #96 holding.
349 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q3 2017.

Based on Insight Capital Research & Management's 13F filing for Q3 2017, filed 15 Nov 2017.